

## DRAFT CARTON TEXT

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

**Nisamox Palatable Tablets 500mg for Dogs**

### 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Nisamox Palatable Tablets 500mg for Dogs are for oral administration to dogs: each tablet contains Amoxicillin 400 mg (as Amoxicillin Trihydrate) and Clavulanic Acid 100 mg (as Potassium Clavulanate), and 2.45 mg of Lake Carmosine (E122).

### 3. PHARMACEUTICAL FORM

Tablets.

### 4. PACKAGE SIZE

10 Tablets  
20 Tablets  
25 Tablets  
100 Tablets

### 5. TARGET SPECIES

Dogs

### 6. INDICATION(S)

For the treatment of the following infections caused by beta-lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid:

- Skin infections (including superficial and deep pyodermas) caused by susceptible *Staphylococci*.
- Urinary tract infections caused by susceptible *Staphylococci* or *Escherichia coli*.
- Respiratory infections caused by susceptible *Staphylococci*.
- Enteritis caused by susceptible *Escherichia coli*.

It is recommended to carry out suitable tests for sensitivity when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.

## 7. METHOD AND ROUTE(S) OF ADMINISTRATION

Administration is via the oral route. The dosage rate is 12.5 mg combined actives/kg bodyweight twice daily. The tablets may be crushed and added to a little food.

To ensure a correct dosage, body weight should be determined as accurately as possible to avoid underdosing. Read package leaflet before use. The tablet can be divided into equal halves.

The following table is intended as a guide to dispensing Nisamox Palatable Tablets at the standard dose rate of 12.5 mg/kg twice daily.

Bodyweight (kg)	Number of tablets (500 mg) per dose twice daily
20 kg	½
40 kg	1
60 kg	1½
80 kg	2

### Duration of therapy:

Routine cases involving all indications: The majority of cases respond to between 5 and 7 days therapy.

Chronic or refractory cases: In these cases where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair.

## 8. WITHDRAWAL PERIOD

Not Applicable.

## 9. SPECIAL WARNING(S), IF NECESSARY

Do not use in animals with known cases of hypersensitivity to penicillins or other substances of the beta-lactam group.

Do not use in rabbits, guinea pigs, hamsters or gerbils.

Do not use in animals with serious dysfunction of the kidneys accompanied by anuria or oliguria.

Do not use where resistance to the combination is known to occur.

Do not administer to horses and ruminating animals.

Read the package leaflet before use.

### **Operator Warnings:**

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may

lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Handle this product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

#### **10. EXPIRY DATE**

XX/XX/XXX

#### **11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C. Store in a dry place. Divided tablets should be stored in the blister pack and used within one day. Keep the blister in the outer carton.

#### **12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Any unused product or waste material should be disposed of in accordance with national requirements.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority – UK ONLY

#### **13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

**FOR ANIMAL TREATMENT ONLY**

*<Supply category to be completed nationally>*

#### **14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

**KEEP OUT OF THE REACH AND SIGHT OF CHILDREN**

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**(EU)**

Norbrook Laboratories (Ireland) Ltd.  
Rossmore Industrial Estate  
Monaghan  
Ireland

**(UK)**

Norbrook Laboratories Limited  
Station Works  
Camlough Road  
Newry  
Co. Down  
BT35 6JP  
Northern Ireland

**DISTRIBUTED BY:**

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm: 02000/4260  
ManA 2000

**17. MANUFACTURER'S BATCH NUMBER**

XXXX-XX

**<Supply category to be completed nationally>**

**FURTHER INFORMATION**

Amoxicillin is a broad-spectrum antibiotic active against a wide range of Gram-positive and Gram-negative bacteria. However, many clinically important bacteria produce beta-lactamase enzymes which destroy this antibiotic. Clavulanic acid inactivates these enzymes, rendering the organisms susceptible to the amoxicillin. Studies in laboratory animals have not produced any evidence of teratogenic effects. Use only according to the risk/benefit assessment by the responsible veterinarian.

**DRAFT BLISTER LABEL TEXT**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**NISAMOX PALATABLE TABLETS 500 mg FOR DOGS**

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Norbrook Laboratories Limited

**3. EXPIRY DATE**

XX/XX/XXXX

**4. BATCH NUMBER**

XXXX-XX

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

**FOR ANIMAL TREATMENT ONLY**

Do not store above 25°C

**DRAFT INSERT TEXT**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE:**

**MARKETING AUTHORISATION HOLDER:**

**(EU)**

Norbrook Laboratories (Ireland) Ltd.  
Rossmore Industrial Estate  
Monaghan  
Ireland

**(UK)**

Norbrook Laboratories Limited  
Station Works  
Camlough Road  
Newry  
Co. Down  
BT35 6JP  
Northern Ireland

**MANUFACTURER RESPONSIBLE FOR BATCH RELEASE:**

Norbrook Manufacturing Ltd.  
Rossmore Industrial Estate  
Monaghan  
Ireland

Norbrook Laboratories Limited  
Station Works  
Camlough Road  
Newry  
Co. Down  
BT35 6JP  
Northern Ireland

**DISTRIBUTED BY:**

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nisamox Palatable Tablets 500mg for Dogs.

### **3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

Nisamox Palatable Tablets 500mg for Dogs are for oral administration to dogs. Each Nisamox Palatable Tablet 500 mg for Dogs contains Amoxicillin 400 mg (as Amoxicillin Trihydrate) and Clavulanic Acid 100 mg (as Potassium Clavulanate) and 2.45 mg of Lake Carmosine (E122).

### **4. INDICATION(S)**

For the treatment of the following infections caused by beta-lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid:

- Skin infections (including superficial and deep pyodermas) caused by susceptible *Staphylococci*.
- Urinary tract infections caused by susceptible *Staphylococci* or *Escherichia coli*.
- Respiratory infections caused by susceptible *Staphylococci*.
- Enteritis caused by susceptible *Escherichia coli*.

It is recommended to carry out suitable tests for sensitivity when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.

### **5. CONTRAINDICATIONS**

Do not use in animals with known cases of hypersensitivity to penicillins or other substances of the beta-lactam group.

Do not use in rabbits, guinea pigs, hamsters or gerbils.

Do not use in animals with serious dysfunction of the kidneys accompanied by anuria or oliguria.

Do not use where resistance to the combination is known to occur.

Do not administer to horses and ruminating animals.

### **6. ADVERSE REACTIONS**

Hypersensitivity unrelated to dose can occur with these agents.

Gastrointestinal symptoms (diarrhoea, vomiting) may occur after administration of the product.

Allergic reactions (e.g. skin reactions, anaphylaxia) may occasionally occur.

In case of occurrence of allergic reaction, the treatment should be withdrawn.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

**7. TARGET SPECIES**

Dogs

**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Administration is via the oral route. The dosage rate is 12.5 mg combined actives/kg bodyweight twice daily. The tablets may be crushed and added to a little food. The tablet can be divided into equal halves. To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.

The following table is intended as a guide to dispensing Nisamox Palatable Tablets at the standard dose rate of 12.5 mg/kg twice daily.

Bodyweight (kg)	Number of tablets (500 mg) per dose twice daily
20 kg	½
40 kg	1
60 kg	1½
80 kg	2

Duration of therapy:

Routine cases involving all indications: The majority of cases respond to between 5 and 7 days therapy.

Chronic or refractory cases: In these cases where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair.

**9. WITHDRAWAL PERIOD**

Not Applicable

**10. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25°C; store in a dry place.

Any halved tablet should be returned to the open blister and used within one day.

Keep out of the reach and sight of children.



## 11. SPECIAL WARNINGS

Inappropriate use of the product may increase the prevalence of bacteria resistant to amoxicillin / clavulanic acid.

In animals with hepatic or renal failure, the dosing regimen should be carefully evaluated.

Use of the product should be based on susceptibility testing and take into account local antimicrobial policies. Narrow spectrum antibacterial therapy should be used for first line treatment where susceptibility testing suggests likely efficacy of this approach.

Studies in laboratory animals have not produced any evidence of teratogenic effects. Use only according to the benefit / risk assessment by the responsible veterinarian.

The potential for allergic cross-reactivity with other penicillins should be considered. Penicillins may increase the effect of aminoglycosides. Caution is advised in the use in small herbivores other than those reported in contraindications.

Phenicol, macrolides, sulphonamides and tetracyclines may inhibit the antibacterial effect of penicillins because of the rapid onset of bacteriostatic action.

## 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused product or waste material should be disposed of in accordance with national requirements.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority – UK ONLY

## 13. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

## 14. OTHER INFORMATION

*<Supply category to be completed nationally>*

### **PACKAGE QUANTITIES:**

Packs of 2, 4, 5 and 20 blister strips containing 5 tablets per strip.

Not all pack sizes may be marketed.

### **FURTHER INFORMATION**

Amoxicillin is a broad-spectrum antibiotic active against a wide range of Gram-positive and Gram-negative bacteria. However, many clinically

important bacteria produce beta-lactamase enzymes which destroy this antibiotic. Clavulanic acid inactivates these enzymes, rendering the organisms susceptible to the amoxicillin. Studies in laboratory animals have not produced any evidence of teratogenic effects. Use only according to the risk/benefit assessment by the responsible veterinarian. Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious. Handle this product with great care to avoid exposure, taking all recommended precautions. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention. Wash hands after use.

ManA 2000

**FOR ANIMAL TREATMENT ONLY.**

Approved: 03 June 2019

A handwritten signature in black ink, appearing to read 'J. Webb', with a horizontal line underneath the name.